127 related articles for article (PubMed ID: 11559555)
21. Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue.
Griggs J; Hesketh R; Smith GA; Brindle KM; Metcalfe JC; Thomas GA; Williams ED
Br J Cancer; 2001 Mar; 84(6):832-5. PubMed ID: 11259100
[TBL] [Abstract][Full Text] [Related]
22. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
Wilmes LJ; Pallavicini MG; Fleming LM; Gibbs J; Wang D; Li KL; Partridge SC; Henry RG; Shalinsky DR; Hu-Lowe D; Park JW; McShane TM; Lu Y; Brasch RC; Hylton NM
Magn Reson Imaging; 2007 Apr; 25(3):319-27. PubMed ID: 17371720
[TBL] [Abstract][Full Text] [Related]
23. Dynamic contrast-enhanced MRI in mouse tumors at 11.7 T: comparison of three contrast agents with different molecular weights to assess the early effects of combretastatin A4.
Fruytier AC; Magat J; Neveu MA; Karroum O; Bouzin C; Feron O; Jordan B; Cron GO; Gallez B
NMR Biomed; 2014 Nov; 27(11):1403-12. PubMed ID: 25323069
[TBL] [Abstract][Full Text] [Related]
24. Comparison of two vascular-disrupting agents at a clinically relevant dose in rodent liver tumors with multiparametric magnetic resonance imaging biomarkers.
Wang H; Cona MM; Chen F; Yu J; Feng Y; Li J; Keyzer FD; Marchal G; Ni Y
Anticancer Drugs; 2012 Jan; 23(1):12-21. PubMed ID: 21857503
[TBL] [Abstract][Full Text] [Related]
25. [Gadolinium-loaded nanoparticle as a novel molecular imaging contrast agent for magnetic resonance imaging].
Liu LZ; Guo GJ; Zeng MS; Lü YC; Liu XW; Cui CY; Wu PH; Li L
Zhonghua Yi Xue Za Zhi; 2007 Jan; 87(4):240-3. PubMed ID: 17425867
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of anti-vascular therapy with texture analysis.
Chen G; Jespersen S; Pedersen M; Pang Q; Horsman MR; Stødkilde Jørgensen H
Anticancer Res; 2005; 25(5):3399-405. PubMed ID: 16101155
[TBL] [Abstract][Full Text] [Related]
27. Trapping effect on a small molecular drug with vascular-disrupting agent CA4P in rodent H22 hepatic tumor model: in vivo magnetic resonance imaging and postmortem inductively coupled plasma atomic emission spectroscopy.
Gao M; Yao N; Huang D; Jiang C; Feng Y; Li Y; Lou B; Peng F; Sun Z; Ni Y; Zhang J
J Drug Target; 2015 Jun; 23(5):436-43. PubMed ID: 25582132
[TBL] [Abstract][Full Text] [Related]
28. Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS.
Beauregard DA; Pedley RB; Hill SA; Brindle KM
NMR Biomed; 2002 Apr; 15(2):99-105. PubMed ID: 11870905
[TBL] [Abstract][Full Text] [Related]
29. Reduced tumor oxygenation by treatment with vinblastine.
Sersa G; Krzic M; Sentjurc M; Ivanusa T; Beravs K; Cemazar M; Auersperg M; Swartz HM
Cancer Res; 2001 May; 61(10):4266-71. PubMed ID: 11358854
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4.
Griggs J; Skepper JN; Smith GA; Brindle KM; Metcalfe JC; Hesketh R
Am J Pathol; 2002 Mar; 160(3):1097-103. PubMed ID: 11891206
[TBL] [Abstract][Full Text] [Related]
31. Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers.
Liu YW; De Keyzer F; Feng YB; Chen F; Song SL; Swinnen J; Bormans G; Oyen R; Huang G; Ni YC
World J Gastroenterol; 2018 Jul; 24(25):2710-2721. PubMed ID: 29991876
[TBL] [Abstract][Full Text] [Related]
32. Combretastatin A4-induced differential cytotoxicity and reduced metastatic ability by inhibition of AKT function in human gastric cancer cells.
Lin HL; Chiou SH; Wu CW; Lin WB; Chen LH; Yang YP; Tsai ML; Uen YH; Liou JP; Chi CW
J Pharmacol Exp Ther; 2007 Oct; 323(1):365-73. PubMed ID: 17646428
[TBL] [Abstract][Full Text] [Related]
33. Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer.
Ng QS; Goh V; Carnell D; Meer K; Padhani AR; Saunders MI; Hoskin PJ
Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1375-80. PubMed ID: 17275203
[TBL] [Abstract][Full Text] [Related]
34. Decrease in tumor apparent permeability-surface area product to a MRI macromolecular contrast medium following angiogenesis inhibition with correlations to cytotoxic drug accumulation.
Daldrup-Link HE; Okuhata Y; Wolfe A; Srivastav S; Øie S; Ferrara N; Cohen RL; Shames DM; Brasch RC
Microcirculation; 2004; 11(5):387-96. PubMed ID: 15280064
[TBL] [Abstract][Full Text] [Related]
35. Detecting early response to cyclophosphamide treatment of RIF-1 tumors using selective multiple quantum spectroscopy (SelMQC) and dynamic contrast enhanced imaging.
Poptani H; Bansal N; Graham RA; Mancuso A; Nelson DS; Glickson JD
NMR Biomed; 2003 Apr; 16(2):102-11. PubMed ID: 12730951
[TBL] [Abstract][Full Text] [Related]
36. Non-invasive imaging of combretastatin activity in two tumor models: Association with invasive estimates.
Nielsen T; Murata R; Maxwell RJ; Stødkilde-Jørgensen H; Ostergaard L; Ley CD; Kristjansen PE; Horsman MR
Acta Oncol; 2010 Oct; 49(7):906-13. PubMed ID: 20831477
[TBL] [Abstract][Full Text] [Related]
37. Tumor physiologic response to combretastatin A4 phosphate assessed by MRI.
Zhao D; Jiang L; Hahn EW; Mason RP
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):872-80. PubMed ID: 15936572
[TBL] [Abstract][Full Text] [Related]
38. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug.
Grosios K; Holwell SE; McGown AT; Pettit GR; Bibby MC
Br J Cancer; 1999 Dec; 81(8):1318-27. PubMed ID: 10604728
[TBL] [Abstract][Full Text] [Related]
39. Comparison of tumor blood perfusion assessed by dynamic contrast-enhanced MRI with tumor blood supply assessed by invasive imaging.
Graff BA; Benjaminsen IC; Brurberg KG; Ruud EB; Rofstad EK
J Magn Reson Imaging; 2005 Mar; 21(3):272-81. PubMed ID: 15723369
[TBL] [Abstract][Full Text] [Related]
40. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.
Galbraith SM; Chaplin DJ; Lee F; Stratford MR; Locke RJ; Vojnovic B; Tozer GM
Anticancer Res; 2001; 21(1A):93-102. PubMed ID: 11299795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
